Phase 3 Clinical Trial for High-Risk Locally Advanced Cervical Cancer Treatment

Strategic Insights -

National Cancer Institute (NCI) has announced an interventional clinical trial to investigate the effectiveness of adding induction chemotherapy to the standard treatment of chemotherapy and radiation for high-risk locally advanced cervical cancer. The Phase 3 trial, led by principal investigator Jyoti S Mayadev, aims to enroll 336 participants from the USA and compare two treatment approaches: one with induction chemotherapy, carboplatin, paclitaxel, and pembrolizumab, followed by chemotherapy and radiation, and another with chemotherapy and radiation followed by pembrolizumab maintenance.

Key Takeaways:

  • The trial will compare the addition of induction chemotherapy to the standard treatment of chemotherapy and radiation for high-risk locally advanced cervical cancer.
  • The trial aims to enroll 336 participants from the USA and will investigate the effectiveness of two treatment approaches.
  • The treatment approaches involve the use of chemotherapy, radiation, and immunotherapy with monoclonal antibodies, such as pembrolizumab.
  • The trial is being led by principal investigator Jyoti S Mayadev and is being conducted by the National Cancer Institute (NCI).
  • The trial's purpose is to determine whether adding induction chemotherapy to the standard treatment can improve outcomes for patients with high-risk locally advanced cervical cancer.

Statistics:

  • The trial aims to enroll 336 participants from the USA.
  • The trial will compare two treatment approaches: induction chemotherapy with carboplatin, paclitaxel, and pembrolizumab followed by chemotherapy and radiation, versus chemotherapy and radiation followed by pembrolizumab maintenance.
  • The trial will utilize chemotherapy, radiation, and immunotherapy with monoclonal antibodies, such as pembrolizumab.
  • The trial is a Phase 3 clinical trial.

Sources:

  • ClinicalTrials.gov. Study ID: NCT40761977. [Viewed: July 14, 2024]
  • National Cancer Institute. [No specific date provided]